

CITATION REPORT

List of articles citing

Amiodarone-induced polymorphous ventricular tachycardia

DOI: 10.1016/0002-8703(83)90270-3
American Heart Journal, 1983, 105, 6-12.

Source: <https://exaly.com/paper-pdf/16389808/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
127	Amiodarone: individualizing dosage with serum concentrations. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1983 , 6, 1327-35	1.6	19
126	Clinical efficacy of amiodarone in treatment of recurrent ventricular tachycardia and ventricular fibrillation. <i>American Heart Journal</i> , 1983 , 106, 887-94	4.9	97
125	Evaluation of amiodarone therapy in the treatment of drug-resistant cardiac arrhythmias: long-term follow-up. <i>American Heart Journal</i> , 1983 , 106, 943-50	4.9	48
124	Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. 1983 , 52, 975-9		128
123	Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. 1983 , 2, 1114-28		191
122	Ten years of experience with amiodarone. <i>American Heart Journal</i> , 1983 , 106, 957-64	4.9	64
121	Amiodarone: the experience of the past decade. 1983 , 287, 1654-6		28
120	Torsade de pointes after amiodarone withdrawal; effects of mild hypokalaemia on repolarization. 1984 , 5, 510-2		9
119	Sotalol, hypokalaemia, syncope, and torsade de pointes. 1984 , 51, 157-62		127
118	Serious adverse effects of amiodarone. 1984 , 7, 131-7		22
117	Polymorphous ventricular tachycardia associated with a marked prolongation of the Q-T interval induced by amiodarone. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1984 , 7, 341-5	1.6	12
116	Ventricular Fibrillation II: Progress Report since 1971. 1984 , 2, 395-419		1
115	Sotalol-induced torsade de pointes. 1984 , 10, 167-70		3
114	Ventricular tachyarrhythmias complicating the idiopathic or acquired long QT syndrome: a reentry in the His-Purkinje system?. 1984 , 17, 103-4		
113	Torsade de pointes induced by N-acetylprocainamide. 1984 , 4, 621-4		78
112	Long QT: good, bad or indifferent?. 1984 , 4, 398-413		198
111	Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. 1984 , 3, 1059-71		194

110	Ventricular tachyarrhythmias complicating amiodarone therapy in the presence of hypokalemia. 1984 , 53, 1462-3		16
109	Amiodarone-induced ventricular tachyarrhythmias. <i>American Heart Journal</i> , 1984 , 107, 610-1	4.9	7
108	Sotalol-induced torsade de pointes. <i>American Heart Journal</i> , 1984 , 107, 179-80	4.9	46
107	Clinical use and pharmacology of amiodarone. 1984 , 68, 1339-66		31
106	Ventricular tachyarrhythmias in the long QT syndromes. 1984 , 68, 1079-109		78
105	Arrhythmias in patients with drug toxicity, electrolyte, and endocrine disturbances. 1984 , 68, 1051-78		31
104	Cardiac glycosides and drugs used in dysrhythmias. 1985 , 9, 158-170		
103	Inhomogeneity of ventricular refractory period in canine heart with quinidine-induced long QT interval: a comparative study on effects of heart rate, isoprenaline, and lignocaine. 1985 , 19, 623-30		5
102	Evaluation of amiodarone therapy in the treatment of drug-resistant cardiac arrhythmias: long term follow-up. 1985 , 6 Suppl D, 151-62		4
101	Life-threatening ventricular arrhythmias provoked by amiodarone treatment. 1985 , 4, 169-76		4
100	Amiodarone: pharmacology and antiarrhythmic and adverse effects. 1985 , 5, 298-313		44
99	Ventricular fibrillation. 1985 , 5, 43B-54B		56
98	Torsades de pointes. A clearly defined syndrome or an electrocardiographic curiosity?. 1985 , 7, 421-7		2
97	Torsades de pointes. 1985 , 3, 289-94		2
96	QT interval prolongation. 1985 , 3, 221-5		10
95	Effect of low oral doses of disopyramide and amiodarone on ventricular and atrial arrhythmias of chagasic patients with advanced myocardial damage. 1985 , 9, 425-38		11
94	Side effects and complications of amiodarone therapy. <i>American Heart Journal</i> , 1985 , 109, 975-83	4.9	176
93	The clinical significance of polymorphic ventricular tachycardia provoked at electrophysiologic testing. <i>American Heart Journal</i> , 1985 , 110, 17-24	4.9	10

92	Control of cardiac arrhythmias by selective lengthening of repolarization: theoretic considerations and clinical observations. <i>American Heart Journal</i> , 1985 , 109, 421-30	4.9	118
91	Epicardial activation patterns of torsade de pointes in canine hearts with quinidine-induced long QT interval but without myocardial infarction. <i>American Heart Journal</i> , 1986 , 111, 1080-7	4.9	19
90	Two cases of sudden death documented by Holter monitor during Secondary Prevention Reinfarction Nifedipine Trial (SPRINT). <i>American Heart Journal</i> , 1986 , 111, 1011-3	4.9	1
89	Long-term tolerance of amiodarone treatment for cardiac arrhythmias. 1986 , 57, 1288-93		52
88	Relation of serum reverse T3 to amiodarone antiarrhythmic efficacy and toxicity. 1986 , 57, 128-30		16
87	Amiodarone and hypokalemia. A dangerous combination. 1986 , 13, 365-8		17
86	Proarrhythmic Responses During Electrophysiologic Testing. 1986 , 4, 487-496		6
85	Amiodarone-induced torsades de pointes. 1986 , 7, 234-9		44
84	Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval. 1986 , 74, 340-9		149
83	Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). 1987 , 316, 844-52		415
82	Clinical, haemodynamic, and antiarrhythmic effects of long term treatment with amiodarone of patients in heart failure. 1987 , 57, 436-45		85
81	Torsade de pointes during loading with amiodarone. 1987 , 8, 541-3		17
80	Cardiac arrhythmias Update 1987. 1987 , 33, 367-432		1
79	Torsades de pointes associated with drugs and toxins: recognition and management. <i>American Heart Journal</i> , 1987 , 113, 1470-82	4.9	113
78	Cutaneous ultrastructural changes and photosensitivity associated with amiodarone therapy. 1987 , 16, 779-87		30
77	Amiodarone. 1987 , 316, 455-66		430
76	Proarrhythmic responses during electrophysiologic testing. 1987 , 59, 45E-48E		30
75	Arrhythmogenesis--a European perspective. 1987 , 59, 49E-51E		5

74	A Low Incidence of Proarrhythmia Using Low-Dose Amiodarone. 1988 , 2, 289-295	10
73	The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. 1988 , 31, 115-72	681
72	Proarrhythmic effects of antiarrhythmic drugs in patients with malignant ventricular arrhythmias evaluated by electrophysiologic testing. 1988 , 12, 131-9	61
71	Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. 1988 , 319, 257-62	127
70	Worsening of ventricular tachycardia by amiodarone. 1988 , 28, 406-11	4
69	Amiodarone in the management of cardiac arrhythmias: current concepts. 1988 , 72, 321-58	17
68	Hypertrophic Cardiomyopathy. 1988 , 6, 233-288	29
67	Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy. 1989 , 80, 1063-9	70
66	A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs?. 1989 , 4, 400-11	4
65	A general overview of amiodarone toxicity: its prevention, detection, and management. 1989 , 31, 393-426	91
64	The proarrhythmic effects of amiodarone. 1989 , 31, 439-46	14
63	The efficacy of amiodarone in the treatment of ventricular tachycardia or ventricular fibrillation. 1989 , 31, 319-54	29
62	Efficacy and toxicity of amiodarone for the treatment of supraventricular tachyarrhythmias. 1989 , 31, 355-66	38
61	Amiodarone prophylaxis in hypertrophic obstructive cardiomyopathy. 1989 , 1, 671	2
60	Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations?. 1989 , 14, 172-84	227
59	Adverse effects of amiodarone. Pathogenesis, incidence and management. 1989 , 4, 246-53	25
58	Intraoperative complications in patients receiving amiodarone: characteristics and risk factors. 1989 , 23, 757-63	12
57	Torsade de pointes associated with perhexiline maleate therapy. 1990 , 20, 818-20	5

56	Torsades de pointe with flecainide-amiodarone therapy. 1990 , 16, 342-3		4
55	Intrapleural placement of minitracheostomy--egress of air after insertion does not guarantee correct placement. 1990 , 16, 343-4		
54	Clinical features of arrhythmia aggravation by antiarrhythmic drugs and their implications for basic mechanisms. 1990 , 19, 153-172		14
53	Risk-benefit assessment of amiodarone in the treatment of cardiac arrhythmias. 1990 , 5, 286-304		12
52	Acute treatment of torsades de pointes with amiodarone: proarrhythmic and antiarrhythmic association of QT prolongation. <i>American Heart Journal</i> , 1990 , 119, 185-6	4-9	18
51	Side effects from amiodarone. <i>American Heart Journal</i> , 1991 , 121, 158-71	4-9	110
50	Sudden cardiac death while taking amiodarone therapy: the role of abnormal repolarization. 1991 , 12, 1144-7		7
49	Electrophysiologic mechanisms for ventricular arrhythmias in left ventricular dysfunction: electrolytes, catecholamines and drugs. 1991 , 31, 1053-60		21
48	Value of electrophysiologic studies in hypertrophic cardiomyopathy treated with amiodarone. 1991 , 67, 175-82		38
47	QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. 1991 , 5, 515-30		67
46	Polymorphous ventricular tachycardia associated with acute myocardial infarction. 1991 , 84, 1543-51		129
45	A prospective comparison of class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia. 1991 , 84, 101-8		53
44	Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. 1992 , 43, 69-110		118
43	Acquired long QT syndrome due to antiarrhythmic drugs and bradyarrhythmias. 1992 , 644, 57-73		12
42	Significance of aborted cardiac arrest and sustained ventricular tachycardia in patients referred for treatment therapy of advanced heart failure. <i>American Heart Journal</i> , 1992 , 124, 123-30	4-9	23
41	MS-551: Pharmacological profile of a novel class III antiarrhythmic agent. 1993 , 30, 37-44		10
40	Arrhythmogenic actions of class III antiarrhythmic drugs in spontaneously beating rabbit sino-atrial node cells. 1993 , 24, 1435-42		4
39	Class III antiarrhythmics in overdose. Presenting features and management principles. 1993 , 9, 450-62		15

38	Female Gender as a Risk Factor for Torsades de Pointes Associated With Cardiovascular Drugs. 1993 , 270, 2590		539
37	Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports. 1994 , 17, 197-202		27
36	Proarrhythmia: definition, risk factors, causes, treatment, and controversies. <i>American Heart Journal</i> , 1994 , 128, 575-85	4.9	30
35	Drug-induced torsade de pointes. Incidence, management and prevention. 1994 , 11, 463-76		62
34	Amiodarone: reevaluation of an old drug. 1995 , 122, 689-700		137
33	Electrophysiological effects of MS-551 in humans: a class III antiarrhythmic agent. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1995 , 18, 2022-7	1.6	15
32	Proarrhythmia during drug treatment of supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden death. 1996 , 78, 35-41		125
31	Arrhythmias in hypertrophic cardiomyopathy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997 , 20, 2706-13	1.6	15
30	Polymorphic Ventricular Tachycardia: Primary Prevention, Immediate Evaluation & Management, Long-Term Management, and Experimental & Theoretical Developments. 1997 , 1, 116-122		
29	Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter. <i>American Heart Journal</i> , 1998 , 135, 551-6	4.9	23
28	Risk Factors for Tachycardia Events Caused by Antiarrhythmic Drugs: Experience From the ESVEM Trial. 1998 , 3, 269-274		3
27	Hyponatremia during therapy with amiodarone. <i>Archives of Internal Medicine</i> , 1999 , 159, 2599-600		20
26	Meglumine antimoniate, amiodarone and torsades de pointes: a case report. <i>Resuscitation</i> , 1999 , 42, 65-8	4	8
25	Drug interactions with cisapride: clinical implications. <i>Clinical Pharmacokinetics</i> , 2000 , 39, 49-75	6.2	96
24	Amiodarone-induced long QT and polymorphic ventricular tachycardia. <i>American Journal of Emergency Medicine</i> , 2001 , 19, 246-8	2.9	7
23	T wave alternans for predicting adverse effects of amiodarone in a patient with dilated cardiomyopathy. <i>Japanese Circulation Journal</i> , 2001 , 65, 468-70		6
22	Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sotalolol, using a canine chronic atrioventricular block model. <i>Circulation Journal</i> , 2002 , 66, 758-62	2.9	28
21	Amiodarone-associated "torsade de pointes". Relevance of concomitant cardiovascular medication in a patient with atrial fibrillation and structural heart disease. <i>Clinical Research in Cardiology</i> , 2003 , 92, 889-92		7

20	"Torsade de pointes" in patients with structural heart disease and atrial fibrillation treated with amiodarone, beta-blockers, and digitalis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2006 , 29, 363-6	1.6	18
19	Pro-arrhythmic effects of amiodarone and concomitant rate-control medication. <i>Europace</i> , 2006 , 8, 403-7,9	3.9	22
18	Electrophysiology of ventricular fibrillation and defibrillation. 101-127		
17	QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 699-712	4.1	21
16	Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty. <i>Therapeutic Advances in Drug Safety</i> , 2018 , 9, 475-493	3.5	10
15	Drug-induced torsades de pointes: clinical and experimental observations bearing on mechanism. <i>Developments in Cardiovascular Medicine</i> , 1987 , 164-182		2
14	Antiarrhythmic agents*. <i>Medical Journal of Australia</i> , 1984 , 141, 718-723	4	1
13	Ventricular Tachycardia. 2010 , 1291-1336		
12	?????????K????????????????????continuous hemodiafiltration(CHDF)??????. <i>Journal of the Japanese Society of Intensive Care Medicine</i> , 2010 , 17, 327-332	0	2
11	Ventricular Tachycardia. 2012 , 211-256		
10	Criteria for Proarrhythmia in Patients with Congestive Heart Failure: Use of Electrophysiologic Testing. <i>Developments in Cardiovascular Medicine</i> , 1987 , 117-130		
9	Torsades de Pointe. <i>Developments in Cardiovascular Medicine</i> , 1988 , 46-58		
8	The arrhythmogenic effects of antiarrhythmic drugs. Types, mechanisms and predisposing factors. 1988 , 301-310		
7	Amiodarone. <i>Developments in Cardiovascular Medicine</i> , 1988 , 266-285		
6	The oral antiarrhythmic drugs. <i>Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques</i> , 1990 , 35, 151-247		2
5	Management of patients with hypertrophic cardiomyopathy. <i>Developments in Cardiovascular Medicine</i> , 1991 , 137-157		
4	Klinischer Teil. 1992 , 132-341		
3	Klinischer Teil. 1996 , 141-369		

2 Prophylaxis of Atrial Fibrillation: What are the Benefits and Risks of the Different Antiarrhythmic Drugs?. **1996**, 225-230

1 Role of Drugs in Torsade de Pointes and Triggered Activity. **1995**, 251-289

○